urokinase vs no fibrinolysis | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
Mortality (early) | 1.24 [0.13 12.02] | p=1.00 | 0 | 65 | 2 | Kiil,Schweizer (urokinase), | Pulmonary embolism (early) | no data | Bleeding (early) | 0.61 [0.09 3.97] | p=1.00 | 0 | 20 | 1 | Kiil, | Any improvement in venous patency (early) | 0.73 [0.04 13.69] | p=1.00 | 0 | 19 | 1 | Kiil, | Complete clot lysis (early) | no data | Stroke/intracerebral bleeding (early) | 0.86 [0.05 14.43] | p=1.00 | 0 | 65 | 2 | Kiil,Schweizer (urokinase), | Leg ulceration (late) | 1.00 [0.06 17.07] | p=1.00 | 0 | 44 | 1 | Schweizer (urokinase), | Mortality (late) | no data | Post-thrombotic syndrome (late) | 0.65 [0.18 2.38] | p=1.00 | 0 | 44 | 1 | Schweizer (urokinase), | Complete clot lysis (late) | 2.13 [0.57 7.97] | p=1.00 | 0 | 44 | 1 | Schweizer (urokinase), | Normal venous function (late) | no data | TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |